Impact of Aminoglycosides in Hypotensive Septic Oncology Patients

M.D. Anderson Cancer Center

Status

Enrolling

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Septicemia

Malignant Solid Neoplasm

Treatments

Other: Electronic Health Record Review

Study type

Observational

Funder types

Other

Identifiers

NCT05045963

NCI-2021-01105 (Registry Identifier)

2020-0999 (Other Identifier)

Details and patient eligibility

About

This study evaluates the impact of aminoglycosides in hypotensive septic oncologic patients. In the oncologic patient population, sepsis is a major health concern due to high mortality rates and healthcare costs. Prior research shows aminoglycosides antibiotics are frequently used to treat sepsis, but their clinical impact in hypotensive oncology patients upon the progression of sepsis is not known.

Full description

PRIMARY OBJECTIVE:

I. To assess the impact of beta-lactam (BL) + aminoglycoside (AG) combination therapy in hypotensive septic oncology patients.

OUTLINE:

Patients' medical charts are reviewed retrospectively.

Enrollment

319 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult patients (age >= 18 years) with a diagnosis of sepsis during the index hospital admission identified by International classification of diseases (ICD)-10 codes (as specified below) receiving BL antibiotics within 6 hours prior to or following the onset of hypotension
To be included in the AG group, patients must have received at least 1 dose of intravenous (IV) tobramycin or amikacin in addition to the BL therapy within the above time period

Exclusion criteria

Age < 18 years
Receipt of IV AG outside of the above time frame in the AG group or receipt of IV AG within 48 hours prior to or following the onset of hypotension in the BL backbone group
Pregnancy
Patients not receiving therapy with BL antibiotics